NeVap is dedicated to significantly reducing Ventilator Associated Pneumonia (VAP), a prevalent and severe hospital-acquired infection. Utilizing lean physician development and design methods, NeVap rapidly creates cost-effective medical devices, such as their FDA-approved tube, which reach patients much faster and at a fraction of the development costs compared to other companies. The company focuses on delivering innovative solutions to hospitals, particularly in the Bay Area.
NeVap's impact is underscored by its successful launch of critical airway innovations, driven by a strong management team that includes medical device executives and FDA compliance experts. The advisory board provides strategic guidance, ensuring the company navigates both successes and challenges effectively. Under the leadership of Chair and CEO Brenton Hanlon, NeVap continues to make strides in improving patient outcomes and reducing healthcare costs associated with VAP.
